Rivaroxaban - Generic Drug Details

What are the generic sources for rivaroxaban and what is the scope of patent protection?

Rivaroxaban is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Lupin, Janssen Pharms, Aiping Pharm Inc, Alembic, Ascent Pharms Inc, Aurobindo Pharma Ltd, Biocon Pharma, Breckenridge, Dr Reddys, Invagen Pharms, Macleods Pharms Ltd, MSN, Regcon Holdings, Sciegen Pharms, Sunshine, and Taro, and is included in twenty-three NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Rivaroxaban has twenty-nine patent family members in twenty-five countries.

There are thirty-five drug master file entries for rivaroxaban. Twenty-two suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for rivaroxaban

International Patents:	29
US Patents:	1
Tradenames:	2
Applicants:	18
NDAs:	23
Drug Master File Entries:	35
Finished Product Suppliers / Packagers:	22
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	381
Patent Applications:	7,326
Drug Prices:	Drug price trends for rivaroxaban
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for rivaroxaban
What excipients (inactive ingredients) are in rivaroxaban?	rivaroxaban excipients list
DailyMed Link:	rivaroxaban at DailyMed

See drug prices for rivaroxaban

Recent Clinical Trials for rivaroxaban

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	PHASE3
Xuanwu Hospital, Beijing	PHASE4
Parexel	PHASE1

See all rivaroxaban clinical trials

Generic filers with tentative approvals for RIVAROXABAN

Applicant	Application No.	Strength	Dosage Form
		20MG	TABLET;ORAL
		15MG	TABLET;ORAL
		10MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for rivaroxaban

Drug Class	Factor Xa Inhibitor
Mechanism of Action	Factor Xa Inhibitors

Medical Subject Heading (MeSH) Categories for rivaroxaban

Factor Xa Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for rivaroxaban

B01AF	Direct factor Xa inhibitors
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for RIVAROXABAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XARELTO	Capsules	rivaroxaban	10 mg, 15 mg and 20 mg	022406	1	2022-06-17
XARELTO	Tablets	rivaroxaban	2.5 mg	022406	4	2018-11-19
XARELTO	Tablets	rivaroxaban	10 mg, 15 mg, and 20 mg	022406	8	2015-07-01

US Patents and Regulatory Information for rivaroxaban

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taro	RIVAROXABAN	rivaroxaban	TABLET;ORAL	208557-002	Oct 7, 2025	AB	RX	No	No
Msn	RIVAROXABAN	rivaroxaban	TABLET;ORAL	208546-001	Oct 24, 2025	AB	RX	No	No
Ascent Pharms Inc	RIVAROXABAN	rivaroxaban	TABLET;ORAL	219332-001	May 14, 2025	AB	RX	No	No
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-003	Nov 4, 2011	AB	RX	Yes	Yes					Y

Expired US Patents for rivaroxaban

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011

EU/EMA Drug Approvals for rivaroxaban

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Rivaroxaban Accord	rivaroxaban	EMEA/H/C/005279Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2020-11-16
Mylan Ireland Limited	Rivaroxaban Viatris (previously Rivaroxaban Mylan)	rivaroxaban	EMEA/H/C/005600Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.-------Adults Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2021-11-12
Bayer AG	Xarelto	rivaroxaban	EMEA/H/C/000944Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	no	no	no	2008-09-30

International Patents for rivaroxaban

Country	Patent Number	Title	Estimated Expiration
Argentina	052565	PREVENCION Y TRATAMIENTO DE TRASTORNOS TROMBOEMBOLICOS
Argentina	110413	COMPUESTO 5-CLORO-N-((5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)FENIL]-1,3-OXAZOLIDIN-5-ILMETIL)-2-TIOFENCARBOXAMIDA
Australia	2006208613	Prevention and treatment of thromboembolic disorders
Brazil	PI0606760	prevenção e tratamento de distúrbios tromboembólicos

Supplementary Protection Certificates for rivaroxaban

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261606	48/2008	Austria		PRODUCT NAME: RIVAROXABAN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/08/472/001 - EU/1/08/472/008 20080930
1261606	2008/030	Ireland		PRODUCT NAME: RIVAROXABAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, HYDRATES, HYDRATES OF THE SALTS AND PRODRUGS.; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930
1261606	CA 2008 00050	Denmark		PRODUCT NAME: RIVAROXABAN OG DETS FARMACEUTISK ACCEPTABLE SALTE, HYDRATER, HYDRATER AF SALTENE OG PRODRUGS
1261606	SPC/GB09/008	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/008 GRANTED TO BAYER INTELLECTUAL PROPERTY GMBH IN RESPECT OF THE PRODUCT RIVAROXABAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, HYDRATES, HYDRATES OF THE SALTS AND PRODRUGS, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6352 DATED 16 FEBRUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 OCTOBER 2023.

Rivaroxaban Market Dynamics and Financial Trajectory: Revenue Drivers, Exclusivity Timelines, Patent/Generic Risk, and Key Competitive Moves

Last updated: June 21, 2026

Rivaroxaban (Xarelto, Janssen/Bayer) is a large global oral anticoagulant with continued demand supported by broad labeled use in atrial fibrillation and VTE treatment and prevention. The financial trajectory remains tied to (1) uptake in high-volume AF and VTE indications, (2) persistence and switching from warfarin, (3) market access and pricing in major geographies, and (4) the timing and intensity of generic and “authorized” competition as exclusivities and patent estates roll off.

---

How big is the rivaroxaban market and what has driven revenue growth?

Answer: Revenue has been driven by dominance in oral factor Xa inhibition, expanding guideline-concordant use in nonvalvular atrial fibrillation and VTE pathways, and sustained preference for fixed-dose oral regimens over injectable or monitoring-heavy therapies. Growth and resilience have also been supported by institutional formularies and broad prescriber adoption across oncology-associated thrombosis and orthopedic prophylaxis cohorts.

What indications contribute most to rivaroxaban revenue?

Rivaroxaban commercialization typically maps to three commercial engines:

1. Atrial fibrillation (stroke prevention in nonvalvular AF)
   • High-volume, chronic use drives steady demand and payer coverage efforts.
2. VTE treatment and secondary prevention
   • Includes initial treatment and extended prevention after acute VTE events.
3. VTE prophylaxis in orthopedic settings and after surgery
   • Periodic but high-volume seasons tied to elective orthopedic procedures.

What market dynamics favor Xarelto versus other DOACs?

Key dynamics that historically supported share:

• Dose and regimen fit: predictable oral dosing supports real-world adherence versus warfarin.
• Provider comfort and guideline presence: long clinical track record increases formulary confidence.
• Competitive differentiation via coverage: managed care decisions can keep patients on Xarelto even as generics expand, depending on contracting dynamics.

How does rivaroxaban compare with apixaban and other DOACs on market share behavior?

• Apixaban has often competed strongly in AF, supported by favorable tolerability perceptions and payer preferences in certain formularies.
• Edoxaban and dabigatran compete variably by geography and contracts.
• Rivaroxaban has remained a scale leader in many markets because of entrenched prescribing and dosing flexibility.

---

When does rivaroxaban lose exclusivity and what does that mean for generic entry timing?

Answer: Rivaroxaban’s core branded exclusivity has already been materially eroded by generic entry in many markets. Financial trajectory since then depends on how quickly and deeply generics gained share, and whether branded contracts delayed switching through price and formulary tactics.

What “exclusivity stack” typically mattered for rivaroxaban?

For high-volume small molecules like rivaroxaban, branded protection commonly involved:

• New chemical entity exclusivity in major jurisdictions
• Oral solid dosage form patents (formulations, polymorphs, manufacturing)
• Method-of-use patents tied to dosing regimens or patient subsets
• Pediatric and regulatory exclusivity add-ons where applicable
• Orphan exclusivity if any applies to specific labeled cohorts

What is the generic entry risk profile for rivaroxaban?

• High on pure compound and straightforward formulations once multiple patents expire.
• Moderate if remaining patents cover specific regimens, strengths, or tablet performance characteristics.
• Practical mitigation through brand contracting and patient retention.

How does the loss of exclusivity typically impact financial performance?

Post-expiry dynamics usually show:

• Rapid price erosion after generic launch.
• Slower volume decline if prescriber inertia and payer contracting favor the incumbent or a preferred competitor.
• Margin compression for the brand due to direct competition and channel inventory normalization.

---

What patents protect rivaroxaban and how does patent life affect commercialization?

Answer: The patent estate historically covered the active ingredient, key solid-state formulation and manufacturing approaches, and dosing/method-of-use regimens. As the estate expires country by country, generic competitors can target carve-outs unless they design around protected features.

How many patent families cover rivaroxaban, and what are the main categories?

Patent coverage typically clusters into:

1. Compound and key analogs
2. Formulation patents
   • Tablet composition, release profile, and stability-related characteristics.
3. Manufacturing process patents
   • Granulation, compression, scale-up controls.
4. Method-of-use / dosing regimen patents
   • Specific dosing steps, intervals, or patient stratification.

Which jurisdictions matter most for generic risk?

• United States: Orange Book listings, Hatch-Waxman Paragraph IV pathways, and district-court leverage.
• European Union: national patent enforcement (validated EPs) plus EMA product authorization realities.
• United Kingdom: UK patent enforcement under UK regimes post-Brexit.
• Japan and major LATAM/MENA markets: patent validity and local enforcement strength can differ.

---

What is the Orange Book status of rivaroxaban in the United States?

Answer: Rivaroxaban’s branded status is reflected in FDA’s Orange Book listings for Xarelto and its strengths, with listed patents typically including formulation and method-of-use coverage. As generics enter, the Orange Book transitions from single-brand dominance to a multi-product competitive set tied to ANDA approvals and exclusivity carve-outs.

How to interpret Orange Book behavior for rivaroxaban

• If Orange Book listings remain after generic approvals, they signal ongoing enforcement or “skinny label” strategies.
• Patent expiry patterns predict when additional generic players can convert from authorized supply to full independents.

---

How many generics and authorized generics compete with rivaroxaban, and who are the major challengers?

Answer: Competition has broadened beyond a single generic wave. The practical market outcome typically depends on which manufacturers secured launches for each strength and label scope and whether contracts direct demand to a subset of low-cost suppliers.

What competitive plays usually matter in DOACs like rivaroxaban?

• Breadth of ANDA coverage across strengths: a wide portfolio supports pharmacy-level substitution.
• Cost leadership: generic manufacturers with scale and supply-chain advantage can maintain share through price cuts.
• Contracting and PBM dynamics: preferred drug lists decide which competitor captures high-volume scripts.

---

What patent litigation affects rivaroxaban generics and settlements?

Answer: Rivaro­xaban has historically been involved in US Hatch-Waxman litigation cycles when challengers sought to market before expiration of listed patents. The business impact came through settlement terms (entry dates, design-arounds, and carve-out labels), and via injunction risk that can delay or limit launch.

How settlement agreements typically change market timing

• Earlier settlement-driven entry can accelerate erosion even before full patent expiry.
• Later settlement or adverse outcomes can delay launch and preserve brand pricing.
• Design-around label constraints can reduce volume capture by limiting eligible patients.

---

How does rivaroxaban financial trajectory evolve after each generic launch wave?

Answer: Financial effects typically show a repeating pattern: initial demand retention followed by sustained margin compression, then stabilization as generic supply normalizes and payer contracting becomes the dominant driver.

What KPIs best reflect rivaroxaban’s financial trajectory post-expiry?

• Global net sales trends: overall demand and price realization.
• Volume growth versus price decline: distinguishes persistence from pure brand discounting.
• Share of prescriptions: reveals formulary switching speed.
• Strength mix: certain strengths can retain better economics if protected or contracted.
• Regional exposure: markets with later expiry or stronger enforcement can lag erosion.

---

How do pricing and reimbursement policies shape rivaroxaban revenue?

Answer: DOACs are sensitive to payer reimbursement design. Formularies, PBM rebates, and step-therapy policies affect patient movement among DOAC brands and generics.

What policies increase or reduce revenue risk?

• Preferred formulary placement for a generic increases switch rates.
• Step edits requiring prior DOAC use can slow switching from warfarin but may also later allow faster generic migration.
• Substitution rules in pharmacy settings determine how quickly “interchangeable” products convert prescriptions.

What reimbursement differences matter most across geographies?

• EU national pricing and tender systems can move rapidly toward lowest net cost.
• US reimbursement and contracting can create slower, more negotiated erosion.
• Markets with constrained reimbursement can show delayed volume loss but sharp price pressure when substitution is mandated.

---

Does rivaroxaban face biosimilar-like risks?

Answer: No. Rivaroxaban is a small-molecule anticoagulant, not a biologic, so biosimilar frameworks do not apply. The principal competitive risk is generic small-molecule entry and potential “authorized generic” channels.

---

Which formulations and strengths drive the strongest demand and the highest IP sensitivity?

Answer: Demand is typically strongest in widely used AF and VTE strengths, while IP sensitivity tends to cluster around formulation and manufacturing patents that can constrain generic equivalents for specific strengths or release characteristics.

What formulation categories can remain protective even after compound expiry?

• Film coating and tablet performance (e.g., stability and release consistency)
• Solid-state form or polymorph-related protection
• Manufacturing process controls affecting bioavailability equivalence

How do strength-specific protections affect generic market share?

• If only some strengths are immediately launchable, share erodes unevenly.
• Pharmacy substitution may accelerate once all strengths are available and payer policies support switching.

---

What generic entry scenarios could hurt rivaroxaban’s branded earnings?

Answer: The highest earnings risk scenarios include (1) broad multi-strength ANDA launch coverage for full label scope, (2) aggressive pricing from multiple suppliers leading to rapid net price deterioration, and (3) payer contracts shifting preferred status to low-cost competitors.

Low-risk scenario

• Generic launches are delayed due to patent enforcement outcomes or carve-outs.
• Brand retains “preferred” status through contracts and adherence support.

High-risk scenario

• Multiple strengths launch concurrently.
• PBMs and formularies rapidly move to generic preference.

---

Key financial trajectory implications: what matters most for investors and licensors?

Answer: Rivaroxaban’s next financial inflection points are driven less by clinical novelty and more by (1) how quickly generics capture share in each geography, (2) remaining patent estates that constrain full substitution, and (3) contract-driven pricing and formulary positioning.

Actionable business framing for licensing and litigation

• Licensing leverage rises where remaining formulation or method-of-use patents still block generic full-label capture.
• Litigation leverage matters most when listed patents map to large-volume strengths and high-volume use populations.

Actionable business framing for R&D

• Generics and follow-on entrants compete on bioequivalence and cost.
• New product differentiation (if any) must clear technical and regulatory hurdles while navigating the still-relevant patent map for formulations or dosing regimens.

---

Key Takeaways

• Rivaroxaban’s revenue base is anchored in high-volume oral anticoagulation use in atrial fibrillation and VTE care.
• The financial trajectory after exclusivity shifts is dominated by price erosion, payer contracting, and the breadth and label scope of generic launches by strength.
• Patent estates historically covered formulations and dosing-related claims that can delay or partially limit generic substitution even after compound-level expiry.
• For investors and licensors, the key variable is not just patent expiry dates but whether remaining claims block full-label, multi-strength generic competition and how that interacts with PBM and formulary dynamics.

---

FAQs

1. How do PBM preferred drug lists affect rivaroxaban net pricing versus wholesale acquisition cost?
2. What happens to rivaroxaban sales when generics launch for only certain strengths?
3. How do settlement terms in Hatch-Waxman cases influence the exact launch month for rivaroxaban competitors?
4. Which rivaroxaban indication (AF vs VTE) is typically more resistant to post-generic share loss?
5. What are the main formulation patent claim types that can still block generic switching for rivaroxaban tablets?

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration.
2. EMA: Xarelto product information. European Medicines Agency.
3. FDA Drug Approval Reports and prescribing information for Xarelto (rivaroxaban). U.S. Food and Drug Administration.